Investigation of the cytocidal potential of Rhinella jimi skin methanol extracts

Figures & data

Figure 1.  Percentages of growth inhibition of cancerous cells exposed to different concentrations of methanol extracts of Rhinellajimi skin.Effects of methanol extracts of Rhinella jimi skin on the proliferation of cancer cells after exposure for 48 h. Cell growth was analysed according to the techniques described in the materialand methods section. UACC-62, melanoma cells; MCF-7, breast cancer cells; NCIADR/RES, adryamycin-resistant ovarian cancer cells; 786-0, kidney cancer cells; NCI-H460, lung, non-small cancer cells; PC-3, prostate cancer cells; OVCAR-03, ovarian cancer cells; HT-29, colon cancer cells; K562, erythromyeloblastoid leukemia cells.

Figure 2.  Evaluation of the effects of the chemotherapeutic drug doxorrubicin (positive control) against cancerous cells. Effects of chemotherapeutic drug doxorubicin (positive control) on the proliferation of cancer cells after exposure for 48 h. UACC-62, melanoma cells; MCF-7, breast cancer cells; NCIADR/RES, adryamycin-resistant ovarian cancer cells; 786-0, kidney cancer cells; NCI-H460, lung, non-small cancer cells; PC-3, prostate cancer cells; OVCAR-03, ovarian cancer cells; HT-29, colon cancer cells; K562, erythromyeloblastoid leukemia cells.

Table 1.  Comparisons of anti-proliferative activity of methanol extracts of Rhinella jimi and the chemotherapeutic drug doxorrubicin (positive control) against cancerous cells (μg/mL).

	UACC	MCF.7	NCL.460	K.562	OVCAR	PCO.3	HT.29	786-0	NCL.ADR
EM	0.25	0.25	<0.25	>25	<0.25	>2.5	<0.25	<0.25	<0.25
Doxorubicin	>0.25	>2.5	>0.25	>0.25	<0.25	0.25	>2.5	>2.5	ND

786-0, kidney cancer cells; HT-29, colon cancer cells; K562, erythromyeloblastoid leukemia cells; MCF-7, breast cancer cells; NCIADR/RES, adryamycin-resistant ovarian cancer cells; NCI-H460, lung, non-small cancer cells; OVCAR-03, ovarian cancer cells; PC-3, prostate cancer cells; UACC-62, melanoma cells.

Table 2.  Comparisons of EC50 of methanol extracts of Rhinella jimi and the chemotherapeutic drug doxorrubicin (positive control) against cancerous cells (μg/mL).

	UACC	MCF.7	NCL.460	K.562	OVCAR	PCO.3	HT.29	786-0	NCL.ADR
EM	0.25	0.35	0.19	235	0.125	24	0.2	0.25	0.25
Doxorubicin	2.1	3	0.26	0.26	0.125	0.25	20	2.5	≥250

786-0, kidney cancer cells; HT-29, colon cancer cells; K562, erythromyeloblastoid leukemia cells; MCF-7, breast cancer cells; NCIADR/RES, adryamycin-resistant ovarian cancer cells; NCI-H460, lung, non-small cancer cells; OVCAR-03, ovarian cancer cells; PC-3, prostate cancer cells; UACC-62, melanoma cells.